AI study led by Insilico's Alex Zhavoronkov bolsters case for faster, cheaper drug discovery
Drug development is an arduous and expensive business. The promise of artificial intelligence is that machines can wean manufacturers away from the breadth of resources it takes to discover a potentially potent compound, and leverage the medical conditions it could be used to treat. Alex Zhavoronkov, whose Hong Kong-based AI-shop Insilico Medicine has entrenched itself in the tentacles of biopharma R&D, now has some data to bolster the fervor and investment that AI has drummed up.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.